European CHMP recommends license extension of carfilzomib (Kyprolis)

The license extension is in combination with either daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Source:

European Medicines Agency